[The stability of synthesized EGFP mRNA in vitro transfected into human umbilical cord mesenchymal stem cells].
Wang X., Hu P., Liu Z., Yuan Y., Li D.
Laboratory Study, published in Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2013)
- Country
- China
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24103272
Abstract (original English)
To identify human umbilical cord mesenchymal stem cells (hUCMSCs) and increase the stability of the in vitro synthesized EGFP mRNA through modification. Immunophenotype of hUCMSCs was examined by flow cytometry. Adipogenic and osteogenic differentiations were determined by oil red O and alkaline phosphatase staining, respectively. In vitro synthesized EGFP mRNA was modified through polyA tailing, capping and adding base analogues, and then transfected into the hUCMSCs. After transfection, the fluorescence intensity was detected by flow cytometry and cell viability was determined by Trypan blue staining. Flow cytometry revealed that the hUCMSCs were positive for CD29, CD44, CD105, and were negative for CD34, CD45 and HLA-DR. They had the capacity of differentiating into adipocytes and osteoblasts. Through the modification the in vitro synthesized mRNA was more stable than unmodified mRNA, and mRNA transfection had lower cytotoxicity than DNA. Modification can highly improve the stability of in vitro synthesized mRNA, which can be translated into protein in hUCMSCs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.